Spero Therapeutics is actively pursuing collaborations with non-commercial organizations and pharmaceutical partners for scientific expertise and funding support. As a growing clinical stage biopharmaceutical company, we currently have alliances with or receive funding support from the following:
Since its founding, Spero has built strategic partnerships to advance its multi-asset, clinical-stage pipeline, raising over $65 million in committed non-dilutive funding since inception, with the potential to receive up to a total of $130 million in such funding, including potential milestone opportunities and full awards.
We intend to continue collaborating with government agencies, non-profit foundations and pharmaceutical partners to support the development of our product candidates.
Spero Therapeutics welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization.